Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LENALIDOMIDE Cause Transient ischaemic attack? 655 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 655 reports of Transient ischaemic attack have been filed in association with LENALIDOMIDE (LENALIDOMIDE). This represents 0.2% of all adverse event reports for LENALIDOMIDE.

655
Reports of Transient ischaemic attack with LENALIDOMIDE
0.2%
of all LENALIDOMIDE reports
15
Deaths
402
Hospitalizations

How Dangerous Is Transient ischaemic attack From LENALIDOMIDE?

Of the 655 reports, 15 (2.3%) resulted in death, 402 (61.4%) required hospitalization, and 15 (2.3%) were considered life-threatening.

Is Transient ischaemic attack Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LENALIDOMIDE. However, 655 reports have been filed with the FAERS database.

What Other Side Effects Does LENALIDOMIDE Cause?

Diarrhoea (27,576) Fatigue (22,956) Death (19,213) Off label use (17,017) Rash (15,794) Pneumonia (14,807) Plasma cell myeloma (14,191) Neuropathy peripheral (10,215) White blood cell count decreased (9,996) Constipation (9,635)

What Other Drugs Cause Transient ischaemic attack?

APIXABAN (1,157) RIVAROXABAN (820) ADALIMUMAB (604) ASPIRIN (587) ROSIGLITAZONE (585) NAPROXEN (521) LEVOTHYROXINE (517) DABIGATRAN ETEXILATE (471) CLOPIDOGREL BISULFATE (454) SIMVASTATIN (415)

Which LENALIDOMIDE Alternatives Have Lower Transient ischaemic attack Risk?

LENALIDOMIDE vs LENIOLISIB LENALIDOMIDE vs LENOGRASTIM LENALIDOMIDE vs LENVATINIB LENALIDOMIDE vs LEPONEX LENALIDOMIDE vs LERCANIDIPINE

Related Pages

LENALIDOMIDE Full Profile All Transient ischaemic attack Reports All Drugs Causing Transient ischaemic attack LENALIDOMIDE Demographics